Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Séverine VermeireBruce E SandsLaurent Peyrin-BirouletGeert R D'HaensJulian PanésAndres J YarurDouglas C WolfTimothy RitterStefan SchreiberJohn C WoolcottIrene ModestoMichael KeatingKevin ShanJoseph WuMichael V ChioreanFilip BaertMarla C DubinskyMartina GoetschSilvio DaneseBrian G FeaganPublished in: Journal of Crohn's & colitis (2024)
Bio/JAKi-naïve and -experienced patients had clinically meaningful induction and maintenance treatment benefits with etrasimod vs placebo.